CollPlant Biotechnologies Ltd (OPHI) stock
Price, market cap and P/E appear here once daily prices are connected.
CollPlant Biotechnologies Ltd grew revenue 360.4% to $2.37M over fiscal 2025. Free cash flow was -$9.45M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.37M
- Net income
- -$11.49M
- EPS, diluted
- -$9.40
- Free cash flow
- -$9.45M
Valuation needs the share price. It fills in once daily prices are connected.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CollPlant Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About CollPlant Biotechnologies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on medical aesthetics and the 3D bioprinting of tissues and organs. The company develops products based on recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants using proprietary technology. These offerings address indications in tissue repair and aesthetic medicine, encompassing bioinks, dermal and soft tissue fillers, and 3D-bioprinted tissues such as breast implants. CollPlant collaborates with pharmaceutical companies, including Allergan, an AbbVie company, and serves physicians, patients, third-party payors, and the broader medical community.
Company profile, executives and historyCollPlant Biotechnologies stock: common questions
What is OPHI's P/E ratio?
CollPlant Biotechnologies lost money over fiscal 2025 (diluted EPS -$9.40), so it has no meaningful P/E ratio.
How much revenue does CollPlant Biotechnologies make?
CollPlant Biotechnologies reported revenue of $2.37M for fiscal 2025, up 360.4% from a year earlier.
Does CollPlant Biotechnologies pay a dividend?
No. CollPlant Biotechnologies has not paid a cash dividend over the last twelve months.
Who are CollPlant Biotechnologies's competitors?
Companies most similar to CollPlant Biotechnologies by business, industry and size include AVR, FEED, NTRB, HRGN, OSRH.
See a number that looks wrong?